Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)-Reference-Cited by-同舟云学术

Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

Published:2017-07 Issue:7 Volume:12 Page:1161-1166
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Iwama Eiji,Goto Yasushi,Murakami Haruyasu,Harada Taishi,Tsumura Shinsuke,Sakashita Hiroyuki,Mori Yoshiaki,Nakagaki Noriaki,Fujita Yuka,Seike Masahiro,Bessho Akihiro,Ono Manabu,Okazaki Akihito,Akamatsu Hiroaki,Morinaga Ryotaro,Ushijima Shinichiro,Shimose Takayuki,Tokunaga Shoji,Hamada Akinobu,Yamamoto Nobuyuki,Nakanishi Yoichi,Sugio Kenji,Okamoto Isamu

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial;Lee;Lancet Oncol,2012

2. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy;Inoue;J Clin Oncol,2009

3. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant;Sakamoto;Cancer Cell,2011

4. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study;Seto;Lancet Oncol,2013

5. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study;Ou;J Clin Oncol,2016

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification and treatment of lung cancer oncogenic drivers in a diverse safety net setting;Clinical Lung Cancer;2024-08

2. Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older;Clinical Pharmacology & Therapeutics;2024-06-17

3. Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database;Clinical Lung Cancer;2024-06

4. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer;JAMA Network Open;2023-12-15

5. Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review;Cancers;2023-10-11